Share on StockTwits

Shares of Dendreon (NASDAQ:DNDN) have received a consensus recommendation of “Hold” from the seventeen ratings firms that are presently covering the stock, American Banking News reports. Six equities research analysts have rated the stock with a sell rating and ten have issued a hold rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $2.13.

A number of research firms have recently commented on DNDN. Analysts at Zacks reiterated a “neutral” rating on shares of Dendreon in a research note on Thursday, August 14th. They now have a $1.50 price target on the stock. Separately, analysts at R. F. Lafferty downgraded shares of Dendreon from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 13th. Finally, analysts at Credit Suisse reiterated a “neutral” rating on shares of Dendreon in a research note on Wednesday, August 13th. They now have a $1.50 price target on the stock, down previously from $2.50.

Dendreon (NASDAQ:DNDN) remained flat at $1.36 during during mid-day trading trading on Friday. The stock had a trading volume of 420,244 shares. Dendreon has a 1-year low of $1.24 and a 1-year high of $3.52. The stock has a 50-day moving average of $1.85 and a 200-day moving average of $2.37. The company’s market cap is $211.4 million.

Dendreon (NASDAQ:DNDN) last issued its quarterly earnings data on Wednesday, August 20th. The company reported ($0.18) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.18). Analysts expect that Dendreon will post $-0.76 EPS for the current fiscal year.

Dendreon Corporation (NASDAQ:DNDN) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.